Moderna Settles Patent Dispute with Roivant and Arbutus for Up to $2.25 Billion

Moderna has reached a global settlement agreement with Genevant Sciences, a subsidiary of Roivant Sciences, and Arbutus Biopharma, resolving a long-running legal battle over the technology crucial to its COVID-19 vaccine. The deal, announced on March 3, 2026, involves an upfront payment of $950 million to Genevant and Arbutus, with an additional $1.3 billion contingent on the outcome of Moderna’s appeal regarding Section 1498 [Reuters].

Key Terms of the Settlement

• Upfront Payment: $950 million will be paid in July 2026.
• Contingent Payment: An additional $1.3 billion will be paid if Moderna’s appeal is unsuccessful.
• Potential Record Settlement: If the full $2.25 billion is paid, this settlement would be the largest disclosed patent settlement in the pharmaceutical industry and the second largest in any industry [Business Insider].
• Patent Validity: The settlement includes a judgment of no invalidity on the four Genevant/Arbutus patents asserted in the case.
• Licensing Agreement: Genevant grants Moderna a global, non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious diseases, along with a covenant not to sue for certain patents and products.

Background of the Dispute

The lawsuit centered on allegations that Moderna infringed on patents held by Genevant and Arbutus related to lipid nanoparticle (LNP) delivery technology. LNP technology is essential for encapsulating and delivering mRNA molecules into cells, enabling the effectiveness of mRNA vaccines like Moderna’s COVID-19 shot [Strait Times]. The dispute involved claims that Moderna used this technology without proper authorization.

Impact on Moderna and Roivant

Analysts suggest the settlement is favorable for Moderna, as the total payment represents a compact fraction of the company’s substantial COVID-19 vaccine sales. The agreement eliminates future royalty risks for Moderna’s COVID-19 and combination vaccines [STAT News]. Roivant’s board has also approved a $1 billion share repurchase program, including a previously authorized $500 million, following the settlement announcement [Business Insider].

Ongoing Litigation

While this settlement resolves the dispute with Genevant and Arbutus, litigation with Pfizer/BioNTech remains ongoing in the United States, following a favorable Markman ruling in September 2025. Comirnaty, the Pfizer/BioNTech vaccine, currently accounts for approximately two-thirds of global COVID-19 mRNA vaccine sales.

Investor Call

Roivant will host an investor call on March 3, 2026, at 4:45 p.m. ET to discuss the settlement and its implications.